Medicare Covers Weight-Loss Drugs for First Time, Costs $50 Monthly
1h ago|4 min readStandard
Fazen Markets Editorial Desk
Collective editorial team · methodology
medicareglp-1
Fazen Markets Editorial Desk
Collective editorial team · methodology
Trades XAUUSD 24/5 on autopilot. Verified Myfxbook performance. Free forever.
Risk warning: CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. The majority of retail investor accounts lose money when trading CFDs. Vortex HFT is informational software — not investment advice. Past performance does not guarantee future results.
A landmark shift in US healthcare policy will grant millions of older Americans access to blockbuster weight-loss medications. Starting July 1, 2026, Medicare Part D plans can cover GLP-1 receptor agonists for the treatment of obesity alone, not just diabetes. This change, announced on June 27, 2026, follows a statutory mandate and establishes a co-payment target of approximately $50 per month for qualifying beneficiaries. The decision fundamentally alters the addressable market for a drug class with annual sales exceeding $30 billion.
The Medicare program has historically operated under a statutory prohibition, established by the Medicare Modernization Act of 2003, which barred Part D from covering drugs for weight loss. This restriction persisted despite the rising prevalence of obesity among Americans aged 65 and older, which now affects over 40% of the demographic. The current macroeconomic backdrop of elevated healthcare costs and a focus on preventative care created political pressure for change.
The catalyst for this policy reversal was the passage of the Treat and Reduce Obesity Act, which was incorporated into broader budget legislation in late 2025. The Act specifically repealed the 2003 ban, granting the Centers for Medicare & Medicaid Services (CMS) the authority to expand coverage. CMS moved swiftly to implement the change for the 2026 plan year, aligning the start date with the beginning of the federal fiscal year on July 1. This rapid implementation reflects the high priority placed on managing obesity-related comorbidities, which cost Medicare an estimated $60 billion annually.
The financial and demographic scale of this policy change is substantial. An estimated 3 to 4 million Medicare beneficiaries are projected to become eligible for GLP-1 coverage for weight loss. The out-of-pocket cost for beneficiaries is targeted at a maximum of $50 per month, a significant discount from the current retail price of over $1,000 monthly.
| Metric | Before July 1, 2026 | After July 1, 2026 |
|---|---|---|
| Medicare Coverage for Weight Loss | Prohibited | Permitted for qualifying beneficiaries |
| Estimated Monthly Patient Cost | ~$1,300 | ~$50 |
| Eligible Patient Pool | 0 | 3-4 million |
This expansion increases the total US population with insurance coverage for GLP-1s by nearly 10%. The broader pharmaceutical sector, as tracked by the SPDR S&P Pharmaceutical ETF (XPH), has gained 5% year-to-date, partly in anticipation of this demand surge. Medicare spent approximately $5 billion on GLP-1s for diabetes in 2025, a figure expected to rise sharply.
The direct beneficiaries are the dominant GLP-1 manufacturers, primarily NVO (Novo Nordisk) and LLY (Eli Lilly). Analysts project this Medicare expansion could add $10-$15 billion in annual peak sales for the drug class, split between these two firms. Pharmacy benefit managers (PBMs) like CI (Cigna) and CVS (CVS Health) will also see increased revenue from managing these high-cost prescriptions. Providers of weight management services and diagnostic companies focused on cardiometabolic health could experience secondary demand increases.
A significant counter-argument centers on the program's long-term fiscal sustainability. Paying for these drugs for millions of new patients could place immense strain on the Medicare Trust Fund if the projected savings from reduced diabetes and heart disease complications do not materialize for years. Institutional investors have been increasing their long positions in LLY and NVO throughout the first half of 2026, while some are shorting companies producing older, less effective weight-loss treatments. The flow of capital is decisively toward firms with proven GLP-1 assets.
The key immediate catalyst is the July 1, 2026, implementation date. Investor focus will shift to weekly prescription data from firms like IQVIA to gauge initial patient uptake. The second major catalyst is the Q2 2026 earnings season, starting in mid-July, where LLY and NVO management will provide updated guidance.
Analysts will watch for any commentary on manufacturing capacity, as supply constraints have previously limited GLP-1 sales growth. The 50-day moving average for LLY, currently near $850 per share, will serve as a technical support level. The next policy milestone is the announcement of 2027 Medicare Part D premiums in September, which will reveal how plans are pricing in this new, costly benefit. Any indication of higher-than-expected premiums could signal cost concerns.
Common side effects include gastrointestinal issues such as nausea, vomiting, and diarrhea. More serious concerns involve a potential risk of thyroid tumors and pancreatitis. A notable clinical consideration is the loss of lean muscle mass alongside fat, which can be significant without concomitant resistance exercise and protein intake. Patients are advised to discuss these risks thoroughly with their physician before starting treatment.
Most private insurers already covered GLP-1s for weight loss, but often with strict prior authorization requirements like documented previous weight-loss attempts. Medicare's coverage terms, including the $50 co-pay structure, are expected to influence private plan designs, potentially making access easier across the entire US insurance market. This establishes a new national benchmark for obesity care coverage.
Coverage is available through standalone Medicare Part D prescription drug plans and Medicare Advantage plans that include Part D. However, each plan has its own formulary, so the specific GLP-1 drug covered and the exact co-pay may vary. Beneficiaries must check their plan's documents during the Annual Election Period or consult with their plan provider to confirm details.
Medicare's coverage of GLP-1s radically expands the US market for obesity drugs, benefiting manufacturers and altering healthcare cost projections.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.
Vortex HFT is our free MT4/MT5 Expert Advisor. Verified Myfxbook performance. No subscription. No fees. Trades 24/5.
Position yourself for the macro moves discussed above
Start TradingSponsored
Open a demo account in 30 seconds. No deposit required.
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.